When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
HEPA - Hepion rallies on start of mid-stage NASH study
Hepion Pharmaceuticals Inc.
Dosing is underway in an open-label Phase 2 clinical trial, AMBITION, evaluating Hepion Pharmaceuticals' (NASDAQ:HEPA) lead drug CRV431 in patients with F2 (moderate fibrosis) or F3 (advanced fibrosis) nonalcoholic steatohepatitis (NASH).
More news on: Hepion Pharmaceuticals, Inc., Healthcare stocks news, Stocks on the move,